As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteersnews2024-11-18T16:03:59+00:00November 18th, 2024|Endpoints News|
Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edemanews2024-11-18T15:16:33+00:00November 18th, 2024|Endpoints News|
Atlas Venture targets $450M for 14th biotech venture fundnews2024-11-18T14:17:00+00:00November 18th, 2024|Endpoints News|
Novartis strikes radiopharma deal with Ratio worth up to $745Mnews2024-11-18T13:00:29+00:00November 18th, 2024|Endpoints News|
Cybin reports high remission rates for psilocin drug in Phase 2 depression testnews2024-11-18T12:00:42+00:00November 18th, 2024|Endpoints News|
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new fundsnews2024-11-18T12:00:27+00:00November 18th, 2024|Endpoints News|
Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis assetnews2024-11-18T09:09:43+00:00November 18th, 2024|Endpoints News|
Scottish biotech Trogenix debuts with viral immunotherapy platform for cancernews2024-11-18T07:00:06+00:00November 18th, 2024|Endpoints News|
Eisai terminates Phase 3 trial of Dravet drug lorcaserinnews2024-11-17T10:27:08+00:00November 17th, 2024|Endpoints News|
Trump picks RFK Jr. for HHS; AbbVie’s psych implosion; Merck tries staving off Summit; and morenews2024-11-16T11:00:06+00:00November 16th, 2024|Endpoints News|
